Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||A synthetic peptide corresponding to aa 1249-1264 (Cys-RSTLQHPDYLQEYST) from the human c-erbB-4/HER-4 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13789 targets HER-4 in IHC applications and shows reactivity with Human and mouse samples.
The MA5-13789 immunogen is a synthetic peptide corresponding to aa 1249-1264 (Cys-RSTLQHPDYLQEYST) from the human c-erbB-4/HER-4 oncoprotein.
c-erbB-4 is the fourth member of class I receptor kinase family (ErbB). HER-4 is most predominantly expressed in several breast carcinoma cell lines, and in normal skeletal muscle, heart, pituitary, brain, and cerebellum. Breast tumor cell lines T47-D, MDA-MB-453, BT-474 and H3396 are found to have the highest levels of mRNA, and intermediate levels are seen in MCF-7, MDA-MB-330 and MDA-MB-361. Expression of erbB-4 is low or absent in some breast tumor cell lines such as MDA-MB-231, MDA-MB-157, MDA-MB-468, and SKBR-3
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
MA5-13789 was used in immunohistochemistry to study the prognostic and clinical value of Ki67 proliferation index and HER2 expression in luminal breast cancer
|Jerjees DA,Alabdullah M,Green AR,Alshareeda A,Macmillan RD,Ellis IO,Rakha EA||Breast cancer research and treatment (145:317)||2014|
Expression of the epidermal growth factor system in human middle ear cholesteatoma.
MA5-13789 was used in immunohistochemistry to study the expression of the EGFR system in patients with middle ear cholesteatoma
|Thorup MB,Munk M,Poulsen SS,Gaihede M,Nexo E,Sorensen BS,Ovesen T||Acta oto-laryngologica (134:124)||2014|
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.
MA5-13789 was used in immunohistochemistry to study the role and prognostic value of ErbB4 CYT-1 isoform expression in serous ovarian cancer
|Paatero I,Lassus H,Junttila TT,Kaskinen M,Bützow R,Elenius K||Gynecologic oncology (129:179)||2013|
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
MA5-13789 was used in immunohistochemistry to study the clinicopathological significance of cystatin M loss in invasive breast cancer
|Ko E,Park SE,Cho EY,Kim Y,Hwang JA,Lee YS,Nam SJ,Bang S,Park J,Kim DH||Breast cancer research : BCR (12:null)||2011|
Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
MA5-13789 was used in immunohistochemistry to study the prognostic value of c-erbB2 expression in anaplastic astrocytomas
|Gulati S,Ytterhus B,Granli US,Gulati M,Lydersen S,Torp SH||Diagnostic pathology (5:null)||2010|
HER-family gene amplification and expression in resected pancreatic cancer.
MA5-13789 was used in immunohistochemistry to study the immunohistochemical expression of HER1-4 and gene amplification of HER2 in resected pancreatic cancer
|te Velde EA,Franke AC,van Hillegersberg R,Elshof SM,de Weger RW,Borel Rinkes IH,van Diest PJ||European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (35:1098)||2009|
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
MA5-13789 was used in immunohistochemistry to evaluate oncogenic markers with prognostic significance in breast ductal carcinoma in situ
|Altintas S,Lambein K,Huizing MT,Braems G,Asjoe FT,Hellemans H,Van Marck E,Weyler J,Praet M,Van den Broecke R,Vermorken JB,Tjalma WA||The breast journal (15:120)||2009|
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
MA5-13789 was used in immunohistochemistry to study the role of HER4/4ICD and BH3-only protein in tamoxifen-induced apoptosis
|Naresh A,Thor AD,Edgerton SM,Torkko KC,Kumar R,Jones FE||Cancer research (68:6387)||2008|
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
MA5-13789 was used in immunohistochemistry to study the immunohistochemical expression of TACE in endocrine cancers and its potential role in breast cancer apoptosis
|Kirkegaard T,Naresh A,Sabine VS,Tovey SM,Edwards J,Dunne B,Cooke TG,Jones FE,Bartlett JM||American journal of clinical pathology (129:735)||2008|
Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.
MA5-13789 was used in immunohistochemistry to study the coexpression of c-erbB 1-4 receptor proteins in human glioblastomas
|Torp SH,Gulati S,Johannessen E,Dalen A||Journal of experimental and clinical cancer research : CR (26:353)||2007|
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
MA5-13789 was used in immunohistochemistry to identify prognostic indicators of response/resistance to trastuzumab in metastatic breast cancer
|Giuliani R,Durbecq V,Di Leo A,Paesmans M,Larsimont D,Leroy JY,Borms M,Vindevoghel A,Jerusalem G,D'Hondt V,Dirix L,Canon JL,Richard V,Cocquyt V,Majois F,Reginster M,Demol J,Kains JP,Delree P,Keppens C,Sotiriou C,Piccart MJ,Cardoso F||European journal of cancer (Oxford, England : 1990) (43:725)||2007|
Expression of the epidermal growth factor system in endometrioid endometrial cancer.
MA5-13789 was used in immunohistochemistry to study the expression of the EGF system in endometrioid endometrial cancer
|Ejskjaer K,Sørensen BS,Poulsen SS,Forman A,Nexø E,Mogensen O||Gynecologic oncology (104:158)||2007|
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
MA5-13789 was used in immunohistochemistry to study the role of erbB family phosphorylation in osteosarcoma
|Hughes DP,Thomas DG,Giordano TJ,McDonagh KT,Baker LH||Pediatric blood and cancer (46:614)||2006|
Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
MA5-13789 was used in immunohistochemistry to study the immunohistochemical expression of EGFR family members in ovarian granulosa cell tumors
|Leibl S,Bodo K,Gogg-Kammerer M,Hrzenjak A,Petru E,Winter R,Denk H,Moinfar F||Gynecologic oncology (101:18)||2006|
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
MA5-13789 was used in immunohistochemistry to study the morphological and immunophenotypic features of breast carcinomas with basal and myoepithelial differentiation
|Rakha EA,Putti TC,Abd El-Rehim DM,Paish C,Green AR,Powe DG,Lee AH,Robertson JF,Ellis IO||The Journal of pathology (208:495)||2006|
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.
MA5-13789 was used in immunohistochemistry to study the prognostic value of HER3 and HER4 expression in colorectal adenocarcinomas
|Kountourakis P,Pavlakis K,Psyrri A,Rontogianni D,Xiros N,Patsouris E,Pectasides D,Economopoulos T||BMC cancer (6:null)||2006|
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
MA5-13789 was used in immunohistochemistry to study the role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
|Edwards J,Traynor P,Munro AF,Pirret CF,Dunne B,Bartlett JM||Clinical cancer research : an official journal of the American Association for Cancer Research (12:123)||2006|
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
MA5-13789 was used in immunohistochemistry to investigate the association of NRG1 gene rearrangements with poor prognosis in breast cancer treatment
|Prentice LM,Shadeo A,Lestou VS,Miller MA,deLeeuw RJ,Makretsov N,Turbin D,Brown LA,Macpherson N,Yorida E,Cheang MC,Bentley J,Chia S,Nielsen TO,Gilks CB,Lam W,Huntsman DG||Oncogene (24:7281)||2005|
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
MA5-13789 was used in immunohistochemistry to study the prognostic value of EGFR family member expression and phospo-Akt levels in cervical carcinoma treated with radiation therapy
|Lee CM,Shrieve DC,Zempolich KA,Lee RJ,Hammond E,Handrahan DL,Gaffney DK||Gynecologic oncology (99:415)||2005|
Expression of the epidermal growth factor system in human endometrium during the menstrual cycle.
MA5-13789 was used in immunohistochemistry to study the importance of the EGF system in the growth of the human endometrium
|Ejskjaer K,Sørensen BS,Poulsen SS,Mogensen O,Forman A,Nexø E||Molecular human reproduction (11:543)||2005|
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
MA5-13789 was used in immunohistochemistry to investigate the efficacy of the combination of paclitaxel, carboplatin and gefitinib against advanced breast cancer
|Fountzilas G,Pectasides D,Kalogera-Fountzila A,Skarlos D,Kalofonos HP,Papadimitriou C,Bafaloukos D,Lambropoulos S,Papadopoulos S,Kourea H,Markopoulos C,Linardou H,Mavroudis D,Briasoulis E,Pavlidis N,Razis E,Kosmidis P,Gogas H||Breast cancer research and treatment (92:1)||2005|
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
MA5-13789 was used in immunohistochemistry to study the frequency and prognostic value of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma
|Wiseman SM,Makretsov N,Nielsen TO,Gilks B,Yorida E,Cheang M,Turbin D,Gelmon K,Huntsman DG||Cancer (103:1770)||2005|
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
MA5-13789 was used in immunohistochemistry to study the expression of EGFR family members in invasive breast cancers
|Abd El-Rehim DM,Pinder SE,Paish CE,Bell JA,Rampaul RS,Blamey RW,Robertson JF,Nicholson RI,Ellis IO||British journal of cancer (91:1532)||2004|
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
MA5-13789 was used in immunohistochemistry to report on a case of a patient with HER2-overexpressing metastatic breast cancer highly sensitive to trastuzumab treatment
|Mano MS,Awada A,Minisini A,Durbecq V,Di Leo A,Piccart M||Breast (Edinburgh, Scotland) (13:347)||2004|
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
MA5-13789 was used in immunohistochemistry to investigate a specific chromosomal aberration in breast and pancreatic cancer cell lines
|Adélaïde J,Huang HE,Murati A,Alsop AE,Orsetti B,Mozziconacci MJ,Popovici C,Ginestier C,Letessier A,Basset C,Courtay-Cahen C,Jacquemier J,Theillet C,Birnbaum D,Edwards PA,Chaffanet M||Genes, chromosomes and cancer (37:333)||2003|
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling.
MA5-13789 was used in immunohistochemistry and western blot to study the role of CD44 in forming a HSPG/MMP7/HB-EGF/ErbB4 complex and its role in regulating female reproductive organ remodelling
|Yu WH,Woessner JF,McNeish JD,Stamenkovic I||Genes and development (16:307)||2002|
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
MA5-13789 was used in immunocytochemistry to study the localization and function of alternative ErbB4 intracellular domains
|Sundvall M,Peri L,Määttä JA,Tvorogov D,Paatero I,Savisalo M,Silvennoinen O,Yarden Y,Elenius K||Oncogene (26:6905)||2007|
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
MA5-13789 was used in western blot to investigate the mechanism for radioresistance induced by H-RAS V12 in HCT116 cells
|Carón RW,Yacoub A,Zhu X,Mitchell C,Han SI,Sasazuki T,Shirasawa S,Hagan MP,Grant S,Dent P||Molecular cancer therapeutics (4:243)||2005|
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
MA5-13789 was used in western blot to study the role of a dominant-negative EGFR in the radiosensitization of malignant glioma cells
|Lammering G,Valerie K,Lin PS,Mikkelsen RB,Contessa JN,Feden JP,Farnsworth J,Dent P,Schmidt-Ullrich RK||Clinical cancer research : an official journal of the American Association for Cancer Research (7:682)||2001|
avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; avian erythroblastosis oncogene B 4; ERBB4 transcript variant I12DEL; ERBB4 transcript variant I20DEL; human epidermal growth factor receptor 4; p180erbB4; Proto-oncogene-like protein c-ErbB-4; Receptor tyrosine-protein kinase erbB-4; Tyrosine kinase-type cell surface receptor HER4; v-erb-a erythroblastic leukemia viral oncogene homolog 4; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4
ALS19; c-erbB-4; ERBB4; HER4; Mer4; p180erbB4